Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Influenza

Free Subscription Articles published in Drug Saf Retrieve available abstracts of 32 articles: HTML format

Single Articles

July 2022
1. HARPAZ R, DuMouchel W, Van Manen R, Nip A, et al
   Signaling COVID-19 Vaccine Adverse Events.
   Drug Saf. 2022;45:765-780.
   PubMed     Abstract available
   
   
   June 2022
2. SHOAIBI A, Rao GA, Voss EA, Ostropolets A, et al
   Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.
   Drug Saf. 2022;45:685-698.
   PubMed     Abstract available
   
   
   May 2022
3. MARTIN GL, Jouganous J, Savidan R, Bellec A, et al
   Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
   Drug Saf. 2022;45:535-548.
   PubMed     Abstract available
   
   
   April 2022
4. KANT A, Jansen J, van Balveren L, van Hunsel F, et al
   Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
   Drug Saf. 2022;45:319-331.
   PubMed     Abstract available
   
   
   February 2022
5. FERNER RE, Stevens RJ, Anton C, Aronson JK, et al
   Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity.
   Drug Saf. 2022;45:137-144.
   PubMed     Abstract available
   
   
   December 2021
6. LUXI N, Giovanazzi A, Capuano A, Crisafulli S, et al
   COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety.
   Drug Saf. 2021;44:1247-1269.
   PubMed     Abstract available
   
   
   November 2021
7. CLINTON JW, Kiparizoska S, Aggarwal S, Woo S, et al
   Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature.
   Drug Saf. 2021;44:1125-1149.
   PubMed     Abstract available
   
   
   
8. IGUCHI T, Umeda H, Kojima M, Kanno Y, et al
   Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
   Drug Saf. 2021;44:1209-1214.
   PubMed     Abstract available
   
   
   October 2021
9. SALAMANCA DE LA CUEVA I, Cinconze E, Eckermann T, Nwoji U, et al
   Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
   Drug Saf. 2021 Oct 25. pii: 10.1007/s40264-021-01121.
   PubMed     Abstract available
   
   
   September 2021
10. ROCCA E, Gauffin O, Savage R, Vidlin SH, et al
    Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020.
    Drug Saf. 2021;44:987-998.
    PubMed     Abstract available
    
    
    
11. MOORE N, Bosco-Levy P, Thurin N, Blin P, et al
    NSAIDs and COVID-19: A Systematic Review and Meta-analysis.
    Drug Saf. 2021;44:929-938.
    PubMed     Abstract available
    
    
    June 2021
12. BHOWMICK S, Dang A, Vallish BN, Dang S, et al
    Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
    Drug Saf. 2021;44:635-644.
    PubMed     Abstract available
    
    
    April 2021
13. DASGUPTA N
    Safety Consequences of Off-Label Drugs Used for COVID-19.
    Drug Saf. 2021;44:399-402.
    PubMed    
    
    
    
14. GRANDVUILLEMIN A, Drici MD, Jonville-Bera AP, Micallef J, et al
    French Pharmacovigilance Public System and COVID-19 Pandemic.
    Drug Saf. 2021;44:405-408.
    PubMed     Abstract available
    
    
    February 2021
15. MARZOLINI C, Stader F, Leuppi-Taegtmeyer A, Stoeckle M, et al
    Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19.
    Drug Saf. 2021;44:255-257.
    PubMed    
    
    
    January 2021
16. BEYZAROV E, Chen Y, Julg R, Naim K, et al
    Global Safety Database Summary of COVID-19-Related Drug Utilization-Safety Surveillance: A Sponsor's Perspective.
    Drug Saf. 2021;44:95-105.
    PubMed     Abstract available
    
    
    
17. SHAKIR S, Lane S, Davies M
    How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.
    Drug Saf. 2021;44:1-5.
    PubMed    
    
    
    December 2020
18. GARCIA P, Revet A, Yrondi A, Rousseau V, et al
    Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Drug Saf. 2020;43:1315-1322.
    PubMed     Abstract available
    
    
    
19. PETOUSIS-HARRIS H
    Assessing the Safety of COVID-19 Vaccines: A Primer.
    Drug Saf. 2020;43:1205-1210.
    PubMed     Abstract available
    
    
    
20. ZEKARIAS A, Watson S, Vidlin SH, Grundmark B, et al
    Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
    Drug Saf. 2020;43:1309-1314.
    PubMed     Abstract available
    
    
    
21. TRIFIRO G, Massari M, Da Cas R, Menniti Ippolito F, et al
    Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Drug Saf. 2020;43:1297-1308.
    PubMed     Abstract available
    
    
    August 2020
22. OSBORNE V, Davies M, Lane S, Evans A, et al
    Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:809-821.
    PubMed     Abstract available
    
    
    
23. SULTANA J, Cutroneo PM, Crisafulli S, Puglisi G, et al
    Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines.
    Drug Saf. 2020;43:691-698.
    PubMed     Abstract available
    
    
    
24. TUCCORI M, Convertino I, Ferraro S, Cappello E, et al
    The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance.
    Drug Saf. 2020;43:699-709.
    PubMed     Abstract available
    
    
    July 2020
25. MOORE N, Carleton B, Blin P, Bosco-Levy P, et al
    Does Ibuprofen Worsen COVID-19?
    Drug Saf. 2020;43:611-614.
    PubMed    
    
    
    
26. OLRY A, Meunier L, Delire B, Larrey D, et al
    Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same.
    Drug Saf. 2020;43:615-617.
    PubMed    
    
    
    
27. MONTASTRUC JL, Toutain PL
    A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study.
    Drug Saf. 2020;43:657-660.
    PubMed     Abstract available
    
    
    
28. DAVIES M, Osborne V, Lane S, Roy D, et al
    Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment.
    Drug Saf. 2020;43:645-656.
    PubMed     Abstract available
    
    
    June 2020
29. CHANDLER RE, McCarthy D, Delumeau JC, Harrison-Woolrych M, et al
    The Role of Pharmacovigilance and ISoP During the Global COVID-19 Pandemic.
    Drug Saf. 2020;43:511-512.
    PubMed    
    
    
    
30. TRIFIRO G, Crisafulli S, Ando G, Racagni G, et al
    Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?
    Drug Saf. 2020;43:507-509.
    PubMed    
    
    
    May 2020
31. MOORE N
    Chloroquine for COVID-19 Infection.
    Drug Saf. 2020;43:393-394.
    PubMed    
    
    
    December 2019
32. DOS SANTOS G, Nguyen BY, Damaso S, Godderis L, et al
    Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
    Drug Saf. 2019 Dec 28. pii: 10.1007/s40264-019-00893.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: